<DOC>
	<DOCNO>NCT00534885</DOCNO>
	<brief_summary>A double-blind , randomize control clinical trial conduct healthy child age 1 8 year evaluate immunogenicity safety three consecutive lot preservative-free inactivated hepatitis A vaccine ( Healive® ) . Participants complete primary vaccination invite participate follow-up phase . Written inform consent obtain . The follow-up study open-label . These subject visit annually next 5 year blood sample assessment immune persistence induce vaccination .</brief_summary>
	<brief_title>Safety , Immunogenicity , Immune Persistence Study Inactivated Hepatitis A Vaccine</brief_title>
	<detailed_description>The investigated vaccine inactivate , adjuvanted preservative-free hepatitis A vaccine . Each dose contain 250 U HAV antigen 0.5 milliliter . Total 400 subject enrol assigned four group , receive one three lot Healive® establish control vaccine month 0 6 . Anti-HAV titer determine month 1 , 6 7 . Anti-HAV titer 20 mIU/ml define seroprotection . After full immunization schedule , write informed consent obtain subject would like participate follow-up study . Blood sample subject collect month 18 , 30 , 42 , 54 , 66 first injection evaluate seroconversion rate ( SCRs ) geometric mean concentration ( GMCs ) antibody hepatitis A virus . Serological result follow-up study use explore suitable statistical model predict persistence hepatitis A vaccine-induced antibody .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Health child 1 10 year Not participate trial course trial Informed consent Any history allergic reaction convulsion follow vaccination Other know planned vaccination within 1 month prior study study period Any chronic illness/disease include virus hepatitis , tuberculosis epilepsy Presence congenital abnormality , upgrowth obstacle Any history/suspicion/presence neurology Lunacy Any current foreseeable use immunosuppressor ( i.e . corticosteroid , immunoglobulin ) within 1 month prior vaccination period study Contraindication intramuscularly injection due thrombocytopenia bleed disorder Abnormal ALT Positive marker antiHAV HBV（HBsAg）infection Presence fever time vaccination , i.e . body temperature ( mouth ) &gt; 37.0 centigrade .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>inactivate hepatitis A vaccine</keyword>
	<keyword>Healive</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>immune persistence</keyword>
</DOC>